Acurx Pharmaceuticals, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
David P. Luci (CEO) and Robert G. Shawah (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications on August 13, 2026 for the Q2 2026 10-Q (period ended June 30, 2026). Both officers certified that disclosure controls, internal controls over financial reporting are effective, financial statements fairly present the company's condition, and no material weaknesses or fraud were identified. No specific financial data, changes, or business events are disclosed in these exhibit pages.
Why this rating
Routine SOX certification boilerplate with no material events, transactions, or disclosures affecting the business. Standard periodic filing requirement.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.